S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
OTCMKTS:PVCT

Provectus Biopharmaceuticals (PVCT) Stock Price, News & Analysis

$0.19
+0.01 (+5.56%)
(As of 04/17/2024 ET)
Today's Range
$0.14
$0.19
50-Day Range
$0.13
$0.22
52-Week Range
$0.06
$0.22
Volume
60,302 shs
Average Volume
302,368 shs
Market Capitalization
$79.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
PVCT stock logo

About Provectus Biopharmaceuticals Stock (OTCMKTS:PVCT)

Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis; and PV-305 for the treatment of infectious keratitis. The company is also developing oral formulations for adult solid tumor cancers, as well as refractory and relapsed pediatric, and other blood cancers comprising leukemias; PV-10 for the treatment of relapsed and refractory pediatric solid tumor cancers; and other formulations for the treatment of cutaneous canine cancers and healing of full-thickness cutaneous wounds. In addition, it develops oral and intranasal formulations for the treatment of severe acute respiratory syndrome coronavirus 2; gram-positive and gram-negative bacterial infections; oral bacterial infections; and fungal infections; as well as vertebrate development, wound healing, and tissue regrowth. The company has collaboration agreement with Bascom Palmer Eye Institute; and University of Miami. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.

PVCT Stock Price History

PVCT Stock News Headlines

AI “wealth window” is closing soon!
Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.
AI “wealth window” is closing soon!
Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.
Provectus Biopharmaceuticals Inc PVCT
PVCT - Provectus Biopharmaceuticals, Inc.
Provectus: Q1 Earnings Snapshot
See More Headlines
Receive PVCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Provectus Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/17/2024
Next Earnings (Estimated)
5/10/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:PVCT
Previous Symbol
NYSEMKT:PVCT
Employees
4
Year Founded
N/A

Profitability

Net Income
$-3,100,000.00
Net Margins
-555.91%
Pretax Margin
-555.91%

Debt

Sales & Book Value

Annual Sales
$560,000.00
Book Value
($0.02) per share

Miscellaneous

Free Float
369,157,000
Market Cap
$75.47 million
Optionable
Not Optionable
Beta
0.67
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Dominic Rodrigues C.F.A. (Age 55)
    CFA, Chief Operations Consultant & Vice Chairman of the Board
    Comp: $75k
  • Dr. Eric A. Wachter (Age 61)
    Co-Founder & CTO
    Comp: $174.19k
  • Ms. Heather Raines CPA (Age 57)
    Chief Financial Officer
    Comp: $83.33k

PVCT Stock Analysis - Frequently Asked Questions

How have PVCT shares performed in 2024?

Provectus Biopharmaceuticals' stock was trading at $0.0960 on January 1st, 2024. Since then, PVCT shares have increased by 97.9% and is now trading at $0.19.
View the best growth stocks for 2024 here
.

Are investors shorting Provectus Biopharmaceuticals?

Provectus Biopharmaceuticals saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 190,800 shares, an increase of 1,700.0% from the March 15th total of 10,600 shares. Based on an average daily trading volume, of 649,000 shares, the days-to-cover ratio is presently 0.3 days.
View Provectus Biopharmaceuticals' Short Interest
.

When is Provectus Biopharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our PVCT earnings forecast
.

What other stocks do shareholders of Provectus Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Provectus Biopharmaceuticals investors own include Vertex Energy (VTNR), Good Times Restaurants (GTIM), Merck & Co., Inc. (MRK), Oncolytics Biotech (ONC), Cytori Therapeutics (CYTX), (DARA) (DARA), Energy Transfer (ET), Gilead Sciences (GILD), iShares Biotechnology ETF (IBB) and MaxLinear (MXL).

How do I buy shares of Provectus Biopharmaceuticals?

Shares of PVCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:PVCT) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners